Bayesin analysis for cystic fibrosis risks in prenatal and carrier screening

Genetics in Medicine

Volumn 6, Issue 5, 2004, Pages 439-449

  Ogino, Shuji ^a,b,c   Wilson, Robert B ^d   Gold, Bert ^e   Hawley, Pamela ^f   Grody, Wayne W ^g  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CFTR; Counseling; Cystic fibrosis; Probability; Screening

Indexed keywords

ARTICLE; AUTOSOMAL RECESSIVE DISORDER; BAYES THEOREM; CONSULTATION; CYSTIC FIBROSIS; ECHOGRAPHY; ETHNIC DIFFERENCE; FAMILY HISTORY; FETUS RISK; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC RISK; HETEROZYGOTE; HUMAN; PRENATAL SCREENING; PROBABILITY; RISK ASSESSMENT; RISK FACTOR; ETHNIC GROUP; FEMALE; GENETIC SCREENING; GENETICS; HETEROZYGOTE DETECTION; MALE; MUTATION; PEDIGREE; PREGNANCY; PRENATAL DIAGNOSIS;

CFTR PROTEIN, HUMAN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

BAYES THEOREM; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ETHNIC GROUPS; FEMALE; GENETIC COUNSELING; GENETIC SCREENING; HETEROZYGOTE DETECTION; HUMANS; MALE; MUTATION; PEDIGREE; PREGNANCY; PRENATAL DIAGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 4644339181     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.GIM.0000139511.83336.8F     Document Type: Article

References (13)

1. Young ID. Introduction to risk calculation in genetic counseling, 2nd ed. Oxford: Oxford University Press, 1999.
2. Bridge PJ. The calculation of genetic risks: Worked examples in DNA diagnostics, Second Edition ed. Baltimore: The Johns Hopkins University Press, 1997.
3. Ogino S, Wilson RB. Bayesian analysis and risk assessment in genetic counseling and testing. J Mol Diagn 2004;6:1-9.
4. Hodge SE, Flodman PL. Risk calculations: Still essential in the molecular age. Am J Med Genet In press.
5. Ogino S, Wilson RB, Grody WW. Bayesian risk assessment for autosomal recessive diseases: Fetal echogenic bowel with one or no detectable CFTR mutation. J Med Genet 2004;41:e70.
6. Scotet V, De Braekeleer M, Audrezet MP, Quere I, Mercier B, Dugueperoux I et al. Prenatal detection of cystic fibrosis by ultrasonography: A retrospective study of more than 346 000 pregnancies. J Med Genet 2002;39:443-448.
7. Richards CS, Bradley LA, Amos J, Allitto B, Grody WW, Maddalena A et a. Standards and guidelines for CFTR mutation testing. Genet Med 2002;4:379-391.
8. Grody WW, Cutting GR, Klinger KW, Richards CS, Watson MS, Desnick RJ. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet Med 2001;3:149-154.
9. Bobadilla JL, Macek M Jr, Fine JP, Farrell PM. Cystic fibrosis: A worldwide analysis of CFTR mutations-correlation with incidence data and application to screening. Hum Mutat 2002;19:575-606.
10. Ogino S, Wilson RB. Genetic testing and risk assessment for spinal muscular atrophy (SMA). Hum Genet 2002;111:477-500.
11. Richards CS, Grody WW. Prenatal screening for cystic fibrosis: Past, present and future. Expert Rev Mol Diagn 2004;4:49-62.
12. Wald NJ, Morris JK, Rodeck CH, Haddow JE, Palomaki GE. Cystic fibrosis: Selecting the prenatal screening strategy of choice. Prenat Diagn 2003;23:474-483.
13. Wald NJ. Couple screening for cystic fibrosis. Lancet 1991;338:1318-1319.